Posts

FDA Staff Signal Replimune RP1 Melanoma Trial Failure, Slashing Stock

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

US Physicians Cautious About AI‑Driven Home Testing

on

FDA Releases 14 New Drug Rejection Letters After 3‑Month Pause in Transparency Policy

on

Sanofi's R&D chief Ashrafian exits as new CEO Garijo seeks to fix pipeline with former Roche executive Fontoura

on

FDA hearing on Amgen's Tavneos will include findings from an independent review

on

Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue

on

FDA Delays Reviews for Eli Lilly, Sanofi, and Others in New Priority Voucher Program Due to Safety and Efficacy Concerns

on

Nektar Digs Into Mid-Stage Data To Establish Alopecia Efficacy of Rezpeg

on

CDC highlights strong effectiveness of 2024–2025 COVID-19 shots in kids while FDA reviews reports of alleged post-vaccination deaths

on

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025

on

CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks

on

Dyne Therapeutics' z-rostudirsen Shows Durable Efficacy, Supporting Positive Regulatory Outlook

on

Moderna Halts Development of CMV Vaccine After Phase 3 Failure

on

Lilly's Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

on

Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition

on

Capricor Claims FDA Misinterpreted Efficacy Data Leading to Rejection of DMD Therapy

on

Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix

on

FDA Rejection Derails PTC Therapeutics' Rare Disease Hopeful

on

HHS Ends BARDA Funding for Future mRNA Vaccine Development, Citing Efficacy Concerns

on